Introduction and Objective: Prior studies show that interruptions in access to prescribed diabetes technology supplies (continuous glucose monitors CGM and insulin pumps) are associated with adverse clinical outcomes. We aimed to determine the frequency, duration, and causes of interruptions in prescribed diabetes technology supplies experienced by adults with diabetes in an ambulatory endocrinology practice. Methods: An online questionnaire was distributed to adults with diabetes prior to their appointments between November 2024 to December 2025. Patients were asked “How many times have you not had access to your prescribed CGM (and/or insulin pump) in the past 3 months?” and “How many days on average did these interruptions in access last?”. The total days of diabetes technology access interruptions were calculated by multiplying the number of interruptions by the interruption duration. Results: There were 357 responses with mean age of 50±18 years, 58% female, 87% White, 71% publicly insured, 54% type 1 diabetes, and mean A1c of 7.2±1.3%. Of 340 CGM users, 43% reported any CGM access interruption over the prior 3 months, with a median (IQR) of 5 (2-16) days and mean of 13±18 days of CGM interruption, and 17% reporting ≥30 days of interruption. Of 166 pump users, 14% reported any pump access interruption over the prior 3 months, with a median of 3 (2-23) days and mean of 17±27 days of pump interruption, and 26% reporting ≥30 days of interruption. The most common reasons for CGM interruptions were early supply failure and supply company delay reported by 55% and 16%, respectively. Conclusion: Interruptions in access to prescribed diabetes technology supplies were common with a significant subset experiencing extended interruptions. Early supply failure and vendor delays were the main causes for CGM interruptions, indicating areas for future intervention. Additional real-world studies of diabetes technology performance are needed to elucidate barriers to sustained access and ultimately reduce supply interruptions. Disclosure T. Knoerl: None. M. Falciglia: None. A. Welch: None.
KNOERL et al. (Fri,) studied this question.